Company research
Molecular Templates, Inc.
CIK 1183765Updated Sep 26, 2026
Name history
THRESHOLD PHARMACEUTICALS INC · through Aug 1, 2017
Filing activity
Latest filing
50 filings on record · 25-NSE, 8-K, DEFA14A, NT 10-Q, SC 13G/A, DEF 14A.
Recent filings
25-NSE - filed by Nasdaq Stock Market LLC regarding Molecular Templates, Inc.
Entry into a Material Definitive Agreement · Bankruptcy or Receivership · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Triggering Events That Accelerate or Increase a Direct Financial Obligation
Items 1.01, 1.03, 2.03, 2.04, 9.01
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Material Modification to Rights of Security Holders
Items 1.01, 2.03, 3.03, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 5.02, 8.01
8-K filing
Show 5 more recent filings
Financials
FY 2023 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 35,383,000Source | 97,548,000Source | 192,362,000Source | 139,877,000Source |
| Property, Plant and Equipment, NetUSD | 7,393,000Source | 14,632,000Source | 19,309,000Source | 22,254,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 11,523,000Source | 32,190,000Source | 24,983,000Source | 25,218,000Source |
| Assets, CurrentUSD | 16,772,000Source | 68,298,000Source | 148,215,000Source | 101,324,000Source |
| Operating Lease, Right-of-Use AssetUSD | 9,161,000Source | 11,132,000Source | 8,608,000Source | 11,104,000Source |
| Other Assets, NoncurrentUSD | 2,057,000Source | 3,486,000Source | 7,244,000Source | 5,195,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 31,171,000Source | 112,680,000Source | 126,700,000Source | 80,537,000Source |
| Commitments and ContingenciesUSD | — | 0Source | 0Source | 0Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 5,000Source | 56,000Source | 56,000Source | 50,000Source |
| Additional Paid in CapitalUSD | 457,099,000Source | — | — | — |
| Retained Earnings (Accumulated Deficit)USD | -452,892,000Source | -444,768,000Source | -352,050,000Source | -269,041,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | -66,000Source | -48,000Source | 17,000Source |
| Stockholders' Equity Attributable to ParentUSD | 4,212,000Source | -15,132,000Source | 65,662,000Source | 59,340,000Source |
| Additional Paid in Capital, Common StockUSD | — | 429,646,000Source | 417,704,000Source | 328,314,000Source |
| Liabilities and EquityUSD | 35,383,000Source | 97,548,000Source | 192,362,000Source | 139,877,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 17,321,000Source | 57,082,000Source | 46,670,000Source | 37,553,000Source |
| Operating Lease, Liability, CurrentUSD | 2,488,000Source | 2,182,000Source | 2,606,000Source | 2,210,000Source |
| Accounts Payable, CurrentUSD | 1,523,000Source | 504,000Source | 1,612,000Source | 2,350,000Source |
| Operating Lease, Liability, NoncurrentUSD | 9,742,000Source | 12,231,000Source | 9,564,000Source | 12,213,000Source |
| Other Liabilities, NoncurrentUSD | 1,406,000Source | 1,295,000Source | 1,625,000Source | 1,490,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 4,279,000Source | 8,823,000Source | 9,515,000Source | 12,575,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 61,000,000Source | — | — |
| Deferred Revenue, CurrentUSD | 9,031,000Source | 45,573,000Source | 32,937,000Source | 14,014,000Source |
| Deferred Revenue, NoncurrentUSD | — | 5,904,000Source | 33,350,000Source | 4,538,000Source |
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Excluding Current MaturitiesUSD | — | 36,168,000Source | 35,491,000Source | 14,926,000Source |
cash flow · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -8,124,000Source | — | — | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 6,645,000Source | 7,383,000Source | 6,630,000Source | 3,917,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 6,702,000Source | 11,909,000Source | 16,631,000Source | 11,817,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 1,019,000Source | -1,108,000Source | -757,000Source | 499,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -41,820,000Source | -89,024,000Source | -30,387,000Source | -83,797,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 29,095,000Source | 95,317,000Source | -62,440,000Source | -34,663,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 200,000Source | 3,198,000Source | 3,996,000Source | 7,392,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -9,116,000Source | -265,000Source | 92,592,000Source | 58,895,000Source |
| Repayments of Long-term DebtUSD | 27,500,000Source | — | 0Source | 5,176,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -21,841,000Source | 6,028,000Source | -235,000Source | -59,565,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 2,293,000Source | 3,495,000Source | 2,248,000Source | 931,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 6,702,000Source | 11,909,000Source | 16,631,000Source | 11,817,000Source |
| Asset Retirement Obligation, Accretion ExpenseUSD | 111,000Source | 124,000Source | 135,000Source | 125,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 61,000,000Source | — | — |
| DepreciationUSD | 6,700,000Source | 7,700,000Source | 6,600,000Source | 4,100,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | 0Source | -2,155,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -475,000Source | -66,000Source | -442,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | 1,795,000Source | — | 0Source | -1,237,000Source |
| General and Administrative ExpenseUSD | 18,897,000Source | 26,200,000Source | 34,106,000Source | 26,722,000Source |
| Income Tax Expense (Benefit)USD | -11,000Source | 53,000Source | 0Source | 5,000Source |
| Net Income (Loss) Attributable to ParentUSD | -8,124,000Source | -92,718,000Source | -83,009,000Source | -104,916,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -8,124,000Source | -92,718,000Source | -83,009,000Source | -104,916,000Source |
| Operating ExpensesUSD | 67,772,000Source | 108,625,000Source | 118,771,000Source | 119,687,000Source |
| Operating Lease, ExpenseUSD | 3,462,000Source | 3,135,000Source | 3,254,000Source | 3,011,000Source |
| Operating Lease, Impairment LossUSD | — | 600,000Source | 600,000Source | — |
| Proceeds from Issuance of Common StockUSD | — | 0Source | 71,145,000Source | 48,372,000Source |
| Proceeds from Stock Options ExercisedUSD | 1,000Source | 33,000Source | 1,620,000Source | 1,040,000Source |
income statement · annual statements
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -10,466,000Source | -88,871,000Source | -80,074,000Source | -100,842,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -8,135,000Source | -92,665,000Source | -83,009,000Source | -104,911,000Source |
| Income Tax Expense (Benefit)USD | -11,000Source | 53,000Source | 0Source | 5,000Source |
| Net Income (Loss) Attributable to ParentUSD | -8,124,000Source | -92,718,000Source | -83,009,000Source | -104,916,000Source |
| Earnings Per Share, BasicUSD per share | -1.8Source | -1.65Source | — | — |
| Earnings Per Share, DilutedUSD per share | -1.8Source | -1.65Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 4,501,206Source | 56,334,456Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 4,501,206Source | 56,334,456Source | — | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 18,897,000Source | 26,200,000Source | 34,106,000Source | 26,722,000Source |
| Interest and Other IncomeUSD | 1,208,000Source | — | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | 988,000Source | 434,000Source | 1,028,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -8,124,000Source | -92,718,000Source | -83,009,000Source | -104,916,000Source |
| Operating ExpensesUSD | 67,772,000Source | 108,625,000Source | 118,771,000Source | 119,687,000Source |
| Operating Lease, ExpenseUSD | 3,462,000Source | 3,135,000Source | 3,254,000Source | 3,011,000Source |
| Research and Development ExpenseUSD | 48,875,000Source | 82,425,000Source | 84,665,000Source | 92,965,000Source |
Filing attachments
ex99-1.htm · 8-K · 2025-04-24
EX-99.1 2 ex99-1.htm Exhibit 99.1 Molecular P Templates, Inc. DIP Financing Term Sheet a g e | 1 DIP FINANCING PROPOSAL for: April 20, 2025 ATTN: Craig Jalbert, President, Chief Executive Officer Molecular Templates, Inc. 9301 Amberglen Boulevard Suite 100 Austin, TX 78729 K2 HealthVentures LLC, 855 Boylston Street, 10 Floor, Boston, MA 02116 Molecular P Templates, Inc. DIP Financing Term Sheet …
Read attachment ↗